Track topics on Twitter Track topics that are important to you
Prof Schadendorf speaks with ecancer at ESMO 2017 about the METRIC trial in melanoma, which initially showed a survival benefit for trametinib. He reports that, with 5 years of safety and survival data now available, the initial benefits have not...
Original Article: The METRIC trial of tremelimumab, five years onNEXT ARTICLE
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...